Affymax's Hematide Data Fall Short - Toronto Star PDF Print
Toronto StarThe remaining two trials, EMERALD 1 and EMERALD 2, were conducted in dialysis patients and pitted Hematide's ability against that of Amgen's Epogen to

... read more

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.